Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform and a company making a mark in the psychedelic wellness scene, recently released results from a survey conducted on its behalf by The Harris Poll. According to a recent article, the survey showed that 65% of Americans who suffer from various conditions “believe that psychedelic medicine (ketamine, psilocybin and MDMA) should be made available to patients with treatment-resistant anxiety, depression or PTSD. Additionally, 63% of Americans who have used prescription medications to treat anxiety/depression/PTSD noted that while the medication helped, they still experienced residual feelings…” Of the respondents, 18% indicated that the prescribed drugs worsened their condition or did not improve it at all. Further, 83% of Americans living with anxiety, depression or PTSD “would be open to pursuing alternative treatment proven to be more effective than prescription medication with fewer side effects.” In describing psychedelics, a family of promising medicines, Delic co-founder and CEO Matt Stang highlighted their “potential to be more effective than traditional drugs with minimal side effects, giving people their best lives back.”
To view the full article, visit https://ibn.fm/pEYvL
Delic Holdings Corp.
Delic is a leader in new medicines and treatments for a modern world, improving access to health benefits across the country and reframing the conversation on psychedelics. The company owns and operates an umbrella of related businesses, including the largest chain of psychedelic wellness clinics in the country, including Ketamine Infusion Centers and Ketamine Wellness Centers; the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Delic Labs; the premier psychedelic wellness event, Meet Delic; and trusted media and e-commerce platforms Reality Sandwich and Delic Radio. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and effective treatment options to the masses. For more information, visit www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.